ClinicalTrials.gg
CompletedNCT03164928Updated Jul 19, 2024Results posted

Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis

A Phase 3 interventional study of Denosumab and Placebo in Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With and Glucocorticoid-induced Osteoporosis, sponsored by Amgen. Completed at 38 sites in 13 countries. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-07-19.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 64 studies testing denosumab in Osteoporosis — 8 open to participants now, 11 under way, 2 of them phase 3. Denosumab · Osteoporosis.

Enrollment
51st of 64
24 · median 90
Started
2018
with 4 others
Phase 3
24 of 64
2 open now
Registered
36th of 64
by date
Lead sponsor
22 of 64
Amgen

Among the 64 studies testing denosumab in Osteoporosis, this one is the 51st largest by enrollment, is one of 5 that started in 2018, is one of 24 in phase 3, and was the 36th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

8 of the 64 studies testing denosumab in Osteoporosis are open now, in 8 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing denosumab in Osteoporosis, or all of them as a file.
02

Study summary

To evaluate the effect of denosumab on lumbar spine bone mineral density (BMD) Z-score as assessed by dual-energy X-ray absorptiometry (DXA) at 12 months in children 5 to 17 year of age with Glucocorticoid (GC)-induced osteoporosis (GiOP).

03

Conditions studied

  • Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With
  • Glucocorticoid-induced Osteoporosis

Browse trials for

Keywords

  • Denosumab
  • Pediatric GIOP
  • Glucocorticoid-induced
  • Osteoporosis
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects, age 5 to 17 years, inclusive, at the time of .
  • Clinical diagnosis of GiOP as defined by the following (and consistent with the International Society for Clinical Densitometry definition of osteoporosis in children and adolescents [Bishop et al, 2014])
  • A confirmed diagnosis of non-malignant condition(s) requiring treatment with systemic GC (including, but not limited to, chronic rheumatologic, gastrointestinal, neurologic, respiratory, and/or nephrological conditions)
  • Subjects who are on systemic GC only as replacement therapy for adrenal insufficiency are not eligible for the study - Treatment with systemic GC (intravenous or oral) of any duration for the underlying non-malignant condition(s) within the 12 months prior to screening
  • Evidence of at least 1 vertebral compression fracture of Genant grade 1 or higher, as assessed by the central imaging vendor on lateral spine X-rays performed at screening or within 2 months prior to screening; OR, in the absence of vertebral compression fractures, presence of both fracture history (ie, ≥ 2 long-bone fractures by age 10 years or ≥ 3 long-bone fractures at any age up to 17 years) and lumbar spine BMD Z-score ≤ -2.0, as assessed by the central imaging vendor.

    • Subject's legally acceptable representative has provided informed consent when the subject is legally too young to provide informed consent and the subject has provided assent based on local regulations and/or guidelines prior to any study-specific activities/procedures being initiated
  • A confirmed diagnosis of non-malignant condition(s) requiring treatment with systemic GC (including, but not limited to, chronic rheumatologic, gastrointestinal, neurologic, respiratory, and/or nephrological conditions)
  • Subjects who are on systemic GC only as replacement therapy for adrenal insufficiency are not eligible for the study
  • Treatment with systemic GC (intravenous or oral) of any duration for the underlying non malignant condition(s) within the 12 months prior to screening
  • Prepubertal children should be expected to require significant GC use during the study, per investigator opinion

Exclusion criteria

Exclusion criteria will include the following:

  • Current hyperthyroidism (unless well controlled on stable antithyroid therapy)
  • Current clinical hypothyroidism (unless well controlled on stable thyroid replacement therapy)
  • History of hyperparathyroidism
  • Current hypoparathyroidism
  • Duchenne muscular dystrophy with symptomatic cardiac abnormality
  • Current malabsorption
  • Active infection or history of infections
  • History of

    • Any causes of primary or secondary osteoporosis (other than GC use), or previous exposure to non-GC medications, which the investigator considers to have been a major factor contributing to the patient's fracture(s)
    • Current adrenal insufficiency as the sole indication for GC therapy
    • Duchenne muscular dystrophy with symptomatic cardiac abnormality
    • Current malabsorption (in children with serum albumin -lower limit of normal [LLN], malabsorption should be clinically ruled out by the investigator to confirm eligibility)
    • Known intolerance to calcium or vitamin D supplements
    • Active infection or history of infections, defined as follows:
  • Any active infection for which systemic anti-infectives were used within 4 weeks prior to screening
  • Serious infection, defined as requiring hospitalization or intravenous anti infectives within 8 weeks prior to screening
  • Recurrent or chronic infection or other active infection that, in the opinion of the investigator, might compromise the safety of the subject
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Other
    Placebo

    SC Q6M placebo

    Other: Placebo

  • Experimental
    Denosumab

    1 mg/kg BW (up to a maximum of 60 mg) SC Q6M

    Drug: Denosumab

Interventions

  • 1mg/kg BW (up to a maximum of 60 mg) SC Q6M

  • OtherPlacebo

    SC Q6M placebo

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Lumbar Spine BMD Z-score as Assessed by Dual-energy X-ray Absorptiometry (DXA) at 12 Months

    Lumbar spine BMD was assessed by DXA and analyzed by analysis of covariance (ANCOVA) including treatment (denosumab vs placebo), baseline age, and baseline BMD z-score. DXA results were converted to z-scores, indicating number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify lumbar spine BMD improvement.

    Time frame: Baseline and 12 Months

Secondary outcomes

  1. Change From Baseline in Lumbar Spine BMD Z-score as Assessed by DXA at 6, 18, 24, and 36 Months

    Lumbar spine BMD was assessed by DXA and analyzed by repeated measures analysis with randomization group, visit, baseline age, and baseline BMD z-score as fixed effects. Treatment-by-visit was included as an interaction term. DXA results were converted to z-scores, indicating number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify lumbar spine BMD improvement.

    Time frame: Baseline and 6, 18, 24, and 36 Months

  2. Change From Baseline in Proximal Femur BMD Z-score as Assessed by DXA at 6, 12, 18, 24, and 36 Months

    Proximal femur (total hip and femoral neck) BMD was assessed by DXA and analyzed by repeated measures analysis with randomization group, visit, baseline age, and baseline BMD z-score as fixed effects. Treatment-by-visit was included as an interaction term. DXA results were converted to z-scores, indicating number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify proximal femur BMD improvement.

    Time frame: Baseline and 6, 12, 18, 24, and 36 Months

  3. Number of Participants With X-ray Confirmed Long-bone Fractures and/or Vertebral Fractures at 12, 24, and 36 Months

    Number of participants who have at least one long bone fracture or vertebral fracture, and number of participants who have more than one long bone fracture or vertebral fracture.

    Time frame: Month 12, 24, and 36

  4. Number of Participants With Improving Vertebral Fractures at 12, 24, and 36 Months

    Number of participants with improving vertebral fractures. An improving fracture is defined as one showing signs of healing/repair from baseline as assessed by X-ray.

    Time frame: Month 12, 24, and 36

  5. Number of Participants With New and Worsening Vertebral and Non-vertebral Fractures at 12, 24, and 36 Months

    Number of participants who have at least one vertebral fracture or non-vertebral fracture, and number of participants who have more than one vertebral fracture or non-vertebral fracture.

    Time frame: Month 12, 24, and 36

  6. Change From Baseline in Child Health Questionnaire-Parent Form-50 (CHQ-PF-50) Physical Summary Score at 12, 24, and 36 Months

    The CHQ-PF-50 is a 50-item questionnaire to be completed by the parents or guardians of children between 5 and 18 years of age. The physical summary score ranges from 0-100 with higher scores indicating better physical health.

    Time frame: Baseline and month 12, 24, and 36

  7. Change From Baseline in CHQ-PF-50 Psychological Summary Score at 12, 24, and 36 Months

    The CHQ-PF-50 is a 50-item questionnaire to be completed by the parents or guardians of children between 5 and 18 years of age. The psychological summary score ranges from 0-100 with higher scores indicating better psychological health.

    Time frame: Baseline and Month 12, 24, and 36

  8. Change From Baseline in Childhood Health Assessment Questionnaire (CHAQ) Disability Index Score at 12, 24, and 36 Months

    The CHAQ was developed to measure the physical functioning in children 6 months to 18 years of age. It consists of 54 questions related to the child's ability to perform various activities of daily living. Depending on the question asked, each question is scored either 0 to 3 based on the level of difficulty experienced by the child or 0-1 based on whether the child required assistance from another person or used an aid or other device. All CHAQ questions were scored and converted to a total index score ranging from 0-3, where higher scores indicate greater disability.

    Time frame: Baseline and Month 12, 24, and 36

  9. Change From Baseline in Wong-Baker FACES Pain Rating Scale (WBFPRS) at 12, 24, and 36 Months

    The WBFPRS is a horizontal pain scale for children 3-18 years which consists of 6 faces that range from a smiling "no hurt" face with a score of 0 to a crying "hurts worst" face with a score of 10.

    Time frame: Baseline and Month 12, 24, and 36

  10. Change From Baseline in Growth Velocity Z-score (Height) at 12, 24, and 36 Months

    Growth velocity was determined by calculating age-adjusted z-scores for height, weight, and body mass index (BMI). Z-scores represent the number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify increased growth velocity.

    Time frame: Baseline and Month 12, 24, and 36

  11. Change From Baseline in Growth Velocity Z-score (Weight) at 12, 24, and 36 Months

    Growth velocity was determined by calculating age-adjusted z-scores for height, weight, and BMI. Z-scores represent the number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify increased growth velocity.

    Time frame: Baseline and Month 12, 24, and 36

  12. Change From Baseline in Growth Velocity Z-score (BMI) at 12, 24, and 36 Months

    Growth velocity was determined by calculating age-adjusted z-scores for height, weight, and BMI. Z-scores represent the number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify increased growth velocity.

    Time frame: Baseline and Month 12, 24, and 36

  13. Mean Serum Concentration of Denosumab

    Time frame: Day 1, Day 10, Day 30, Month 3, Month 6, Month 12, and Month 18

07

Results

Posted Jul 19, 2024

Participant flow

This study was conducted at 12 center(s) in Australia, Canada, Columbia, India, Peru, Russia, Turkey, Ukraine, and the United States between May 2018 and December 2023.

Participant flow — Overall Study
MilestoneDenosumab/DenosumabPlacebo/Denosumab
Started168
Completed158
Not completed10
Withdrew: Lost to follow-up10

Outcome measures

PrimaryChange From Baseline in Lumbar Spine BMD Z-score as Assessed by Dual-energy X-ray Absorptiometry (DXA) at 12 Months

Lumbar spine BMD was assessed by DXA and analyzed by analysis of covariance (ANCOVA) including treatment (denosumab vs placebo), baseline age, and baseline BMD z-score. DXA results were converted to z-scores, indicating number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify lumbar spine BMD improvement.

Time frame:
Baseline and 12 Months
Reported as:
Least squares mean · Z-score
Change From Baseline in Lumbar Spine BMD Z-score as Assessed by Dual-energy X-ray Absorptiometry (DXA) at 12 Months
Z-scoreDenosumab/DenosumabPlacebo/Denosumab
Change From Baseline in Lumbar Spine BMD Z-score as Assessed by Dual-energy X-ray Absorptiometry (DXA) at 12 Months0.23 (-0.054 to 0.506)0.11 (-0.304 to 0.532)
Statistical analysis
  • Denosumab/Denosumab vs Placebo/Denosumab · ANCOVA · p = 0.68 · Least squares mean difference: 0.11 · 95% CI -0.450 to 0.673
SecondaryChange From Baseline in Lumbar Spine BMD Z-score as Assessed by DXA at 6, 18, 24, and 36 Months

Lumbar spine BMD was assessed by DXA and analyzed by repeated measures analysis with randomization group, visit, baseline age, and baseline BMD z-score as fixed effects. Treatment-by-visit was included as an interaction term. DXA results were converted to z-scores, indicating number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify lumbar spine BMD improvement.

Time frame:
Baseline and 6, 18, 24, and 36 Months
Reported as:
Least squares mean · Z-score
Change From Baseline in Lumbar Spine BMD Z-score as Assessed by DXA at 6, 18, 24, and 36 Months
Z-scoreDenosumab/DenosumabPlacebo/Denosumab
Month 60.28 (0.095 to 0.468)0.11 (-0.176 to 0.391)
Month 180.32 (-0.034 to 0.679)0.30 (-0.206 to 0.800)
Month 240.37 (-0.017 to 0.755)0.26 (-0.285 to 0.801)
Month 36-0.23 (-0.833 to 0.372)0.57 (-0.268 to 1.416)
Statistical analysis
  • Denosumab/Denosumab vs Placebo/Denosumab · Repeated Measures Model · p = 0.34 · Least squares mean difference: 0.17 · 95% CI -0.194 to 0.542
  • Denosumab/Denosumab vs Placebo/Denosumab · Repeated Measures Model · p = 0.93 · Least squares mean difference: 0.03 · 95% CI -0.609 to 0.661
  • Denosumab/Denosumab vs Placebo/Denosumab · Repeated Measures Model · p = 0.74 · Least squares mean difference: 0.11 · 95% CI -0.572 to 0.795
  • Denosumab/Denosumab vs Placebo/Denosumab · Repeated Measures Model · p = 0.12 · Least squares means difference: -0.80 · 95% CI -1.848 to 0.239
SecondaryChange From Baseline in Proximal Femur BMD Z-score as Assessed by DXA at 6, 12, 18, 24, and 36 Months

Proximal femur (total hip and femoral neck) BMD was assessed by DXA and analyzed by repeated measures analysis with randomization group, visit, baseline age, and baseline BMD z-score as fixed effects. Treatment-by-visit was included as an interaction term. DXA results were converted to z-scores, indicating number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify proximal femur BMD improvement.

Time frame:
Baseline and 6, 12, 18, 24, and 36 Months
Reported as:
Least squares mean · Z-score
Change From Baseline in Proximal Femur BMD Z-score as Assessed by DXA at 6, 12, 18, 24, and 36 Months
Z-scoreDenosumab/DenosumabPlacebo/Denosumab
Month 6 (Total Hip)0.22 (-0.103 to 0.552)0.64 (0.104 to 1.171)
Month 12 (Total Hip)0.24 (-0.079 to 0.554)0.30 (-0.168 to 0.759)
Month 18 (Total Hip)0.48 (0.015 to 0.937)0.75 (0.061 to 1.434)
Month 24 (Total Hip)0.52 (0.000 to 1.033)0.69 (-0.062 to 1.447)
Month 36 (Total Hip)0.64 (-0.149 to 1.436)0.73 (-0.384 to 1.850)
Month 6 (Femoral Neck)0.42 (0.000 to 0.849)0.60 (-0.037 to 1.241)
Month 12 (Femoral Neck)0.53 (0.029 to 1.030)0.43 (-0.294 to 1.161)
Month 18 (Femoral Neck)0.85 (0.261 to 1.446)0.48 (-0.387 to 1.350)
Month 24 (Femoral Neck)0.75 (0.000 to 1.495)0.64 (-0.449 to 1.724)
Month 36 (Femoral Neck)1.00 (-0.008 to 2.012)0.63 (-0.798 to 2.050)
Statistical analysis
  • Denosumab/Denosumab vs Placebo/Denosumab · Repeated Measures Model · p = 0.19 · Least squares mean difference: -0.41 · 95% CI -1.050 to 0.223
  • Denosumab/Denosumab vs Placebo/Denosumab · Repeated Measures Model · p = 0.83 · Least squares mean difference: -0.06 · 95% CI -0.631 to 0.515
  • Denosumab/Denosumab vs Placebo/Denosumab · Repeated Measures Model · p = 0.51 · Least squares mean difference: -0.27 · 95% CI -1.108 to 0.565
  • Denosumab/Denosumab vs Placebo/Denosumab · Repeated Measures Model · p = 0.69 · Least squares mean difference: -0.18 · 95% CI -1.098 to 0.746
  • Denosumab/Denosumab vs Placebo/Denosumab · Repeated Measures Model · p = 0.89 · Least squares mean difference: -0.09 · 95% CI -1.465 to 1.286
  • Denosumab/Denosumab vs Placebo/Denosumab · Repeated Measures Model · p = 0.64 · Least squares mean difference: -0.18 · 95% CI -0.969 to 0.614
  • Denosumab/Denosumab vs Placebo/Denosumab · Repeated Measures Model · p = 0.83 · Least squares mean difference: 0.10 · 95% CI -0.808 to 1.000
  • Denosumab/Denosumab vs Placebo/Denosumab · Repeated Measures Model · p = 0.48 · Least squares mean difference: 0.37 · 95% CI -0.697 to 1.442
  • Denosumab/Denosumab vs Placebo/Denosumab · Repeated Measures Model · p = 0.86 · Least squares mean difference: 0.11 · 95% CI -1.222 to 1.443
  • Denosumab/Denosumab vs Placebo/Denosumab · Repeated Measures Model · p = 0.66 · Least squares mean difference: 0.38 · 95% CI -1.378 to 2.130
SecondaryNumber of Participants With X-ray Confirmed Long-bone Fractures and/or Vertebral Fractures at 12, 24, and 36 Months

Number of participants who have at least one long bone fracture or vertebral fracture, and number of participants who have more than one long bone fracture or vertebral fracture.

Time frame:
Month 12, 24, and 36
Reported as:
Count of participants · Participants
Number of Participants With X-ray Confirmed Long-bone Fractures and/or Vertebral Fractures at 12, 24, and 36 Months
ParticipantsDenosumab/DenosumabPlacebo/Denosumab
Month 12 (at least 1 fracture)22
Month 24 (at least 1 fracture)33
Month 36 (at least 1 fracture)33
Month 12 (more than 1 fracture)21
Month 24 (more than 1 fracture)20
Month 36 (more than 1 fracture)31
SecondaryNumber of Participants With Improving Vertebral Fractures at 12, 24, and 36 Months

Number of participants with improving vertebral fractures. An improving fracture is defined as one showing signs of healing/repair from baseline as assessed by X-ray.

Time frame:
Month 12, 24, and 36
Reported as:
Count of participants · Participants
Number of Participants With Improving Vertebral Fractures at 12, 24, and 36 Months
ParticipantsDenosumab/DenosumabPlacebo/Denosumab
Month 1231
Month 2421
Month 3612
SecondaryNumber of Participants With New and Worsening Vertebral and Non-vertebral Fractures at 12, 24, and 36 Months

Number of participants who have at least one vertebral fracture or non-vertebral fracture, and number of participants who have more than one vertebral fracture or non-vertebral fracture.

Time frame:
Month 12, 24, and 36
Reported as:
Count of participants · Participants
Number of Participants With New and Worsening Vertebral and Non-vertebral Fractures at 12, 24, and 36 Months
ParticipantsDenosumab/DenosumabPlacebo/Denosumab
Month 12 (at least 1 fracture)22
Month 24 (at least 1 fracture)33
Month 36 (at least 1 fracture)33
Month 12 (more than 1 fracture)21
Month 24 (more than 1 fracture)20
Month 36 (more than 1 fracture)31
SecondaryChange From Baseline in Child Health Questionnaire-Parent Form-50 (CHQ-PF-50) Physical Summary Score at 12, 24, and 36 Months

The CHQ-PF-50 is a 50-item questionnaire to be completed by the parents or guardians of children between 5 and 18 years of age. The physical summary score ranges from 0-100 with higher scores indicating better physical health.

Time frame:
Baseline and month 12, 24, and 36
Reported as:
Mean · Scores on a scale
Change From Baseline in Child Health Questionnaire-Parent Form-50 (CHQ-PF-50) Physical Summary Score at 12, 24, and 36 Months
Scores on a scaleDenosumab/DenosumabPlacebo/Denosumab
Month 125.26 ± 8.888.53 ± 16.39
Month 245.62 ± 7.3919.88 ± 15.20
Month 364.48 ± 8.8914.18 ± 8.14
SecondaryChange From Baseline in CHQ-PF-50 Psychological Summary Score at 12, 24, and 36 Months

The CHQ-PF-50 is a 50-item questionnaire to be completed by the parents or guardians of children between 5 and 18 years of age. The psychological summary score ranges from 0-100 with higher scores indicating better psychological health.

Time frame:
Baseline and Month 12, 24, and 36
Reported as:
Mean · Scores on a scale
Change From Baseline in CHQ-PF-50 Psychological Summary Score at 12, 24, and 36 Months
Scores on a scaleDenosumab/DenosumabPlacebo/Denosumab
Month 120.71 ± 9.15-0.10 ± 12.52
Month 242.58 ± 12.581.90 ± 9.76
Month 365.20 ± 10.092.00 ± 9.33
SecondaryChange From Baseline in Childhood Health Assessment Questionnaire (CHAQ) Disability Index Score at 12, 24, and 36 Months

The CHAQ was developed to measure the physical functioning in children 6 months to 18 years of age. It consists of 54 questions related to the child's ability to perform various activities of daily living. Depending on the question asked, each question is scored either 0 to 3 based on the level of difficulty experienced by the child or 0-1 based on whether the child required assistance from another person or used an aid or other device. All CHAQ questions were scored and converted to a total index score ranging from 0-3, where higher scores indicate greater disability.

Time frame:
Baseline and Month 12, 24, and 36
Reported as:
Mean · Scores on a scale
Change From Baseline in Childhood Health Assessment Questionnaire (CHAQ) Disability Index Score at 12, 24, and 36 Months
Scores on a scaleDenosumab/DenosumabPlacebo/Denosumab
Month 12-0.06 ± 0.32-0.29 ± 0.44
Month 24-0.09 ± 0.33-0.30 ± 0.49
Month 36-0.12 ± 0.45-0.43 ± 0.45
SecondaryChange From Baseline in Wong-Baker FACES Pain Rating Scale (WBFPRS) at 12, 24, and 36 Months

The WBFPRS is a horizontal pain scale for children 3-18 years which consists of 6 faces that range from a smiling "no hurt" face with a score of 0 to a crying "hurts worst" face with a score of 10.

Time frame:
Baseline and Month 12, 24, and 36
Reported as:
Mean · Scores on a scale
Change From Baseline in Wong-Baker FACES Pain Rating Scale (WBFPRS) at 12, 24, and 36 Months
Scores on a scaleDenosumab/DenosumabPlacebo/Denosumab
Month 12-0.7 ± 3.3-0.3 ± 3.9
Month 24-0.6 ± 2.9-2.4 ± 0.9
Month 36-2.5 ± 1.80.0 ± 1.4
SecondaryChange From Baseline in Growth Velocity Z-score (Height) at 12, 24, and 36 Months

Growth velocity was determined by calculating age-adjusted z-scores for height, weight, and body mass index (BMI). Z-scores represent the number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify increased growth velocity.

Time frame:
Baseline and Month 12, 24, and 36
Reported as:
Mean · Z-score
Change From Baseline in Growth Velocity Z-score (Height) at 12, 24, and 36 Months
Z-scoreDenosumab/DenosumabPlacebo/Denosumab
Month 12-0.18 ± 0.46-0.07 ± 0.84
Month 24-0.11 ± 0.90-0.27 ± 1.17
Month 36-0.33 ± 0.840.01 ± 1.35
SecondaryChange From Baseline in Growth Velocity Z-score (Weight) at 12, 24, and 36 Months

Growth velocity was determined by calculating age-adjusted z-scores for height, weight, and BMI. Z-scores represent the number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify increased growth velocity.

Time frame:
Baseline and Month 12, 24, and 36
Reported as:
Mean · Z-score
Change From Baseline in Growth Velocity Z-score (Weight) at 12, 24, and 36 Months
Z-scoreDenosumab/DenosumabPlacebo/Denosumab
Month 12-0.12 ± 0.44-0.10 ± 0.49
Month 24-0.22 ± 0.73-0.68 ± 0.62
Month 36-0.32 ± 0.90-0.44 ± 0.60
SecondaryChange From Baseline in Growth Velocity Z-score (BMI) at 12, 24, and 36 Months

Growth velocity was determined by calculating age-adjusted z-scores for height, weight, and BMI. Z-scores represent the number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify increased growth velocity.

Time frame:
Baseline and Month 12, 24, and 36
Reported as:
Mean · Z-score
Change From Baseline in Growth Velocity Z-score (BMI) at 12, 24, and 36 Months
Z-scoreDenosumab/DenosumabPlacebo/Denosumab
Month 12-0.03 ± 0.53-0.14 ± 0.54
Month 24-0.12 ± 0.80-0.75 ± 1.02
Month 36-0.12 ± 0.84-0.72 ± 0.97
SecondaryMean Serum Concentration of Denosumab
Time frame:
Day 1, Day 10, Day 30, Month 3, Month 6, Month 12, and Month 18
Reported as:
Mean · ng/mL
Mean Serum Concentration of Denosumab
ng/mLDenosumab/DenosumabPlacebo/Denosumab
Day 10.00 ± 0.00—
Day 1010300 ± 7900—
Day 306830 ± 4770—
Month 31100 ± 935—
Month 6141 ± 338—
Month 12157 ± 3490.00 ± 0.00
Month 1849 ± 1547.61 ± 21.5

Adverse events

Collected over From date of enrollment through last dose, up to 36 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Baseline-Month 12: Placebo0/8 (0%)1/8 (12.5%)5/8 (62.5%)
Baseline-Month 12: Denosumab0/16 (0%)3/16 (18.8%)11/16 (68.8%)
Baseline-Month 24: Placebo/Denosumab0/8 (0%)1/8 (12.5%)5/8 (62.5%)
Baseline-Month 24: Denosumab/Denosumab0/16 (0%)3/16 (18.8%)12/16 (75%)
Baseline-Month 36: Placebo/Denosumab0/8 (0%)2/8 (25%)5/8 (62.5%)
Baseline-Month 36: Denosumab/Denosumab0/16 (0%)4/16 (25%)13/16 (81.3%)
Most frequent serious events
Most frequent serious events
EventBaseline-Month 12: PlaceboBaseline-Month 12: DenosumabBaseline-Month 24: Placebo/DenosumabBaseline-Month 24: Denosumab/DenosumabBaseline-Month 36: Placebo/DenosumabBaseline-Month 36: Denosumab/Denosumab
CardiomyopathyCardiac disorders1/80/161/80/161/80/16
UreterolithiasisRenal and urinary disorders0/80/160/80/161/80/16
Autoimmune hepatitisHepatobiliary disorders0/81/160/81/160/81/16
Urinary tract infectionInfections and infestations0/80/160/80/160/81/16
Brain contusionInjury, poisoning and procedural complications0/81/160/81/160/81/16
Femur fractureInjury, poisoning and procedural complications0/81/160/81/160/81/16
Tibia fractureInjury, poisoning and procedural complications0/81/160/81/160/81/16
Uterine haemorrhageReproductive system and breast disorders0/81/160/81/160/81/16
Most frequent other events
Showing 10 of 82
Most frequent other events
EventBaseline-Month 12: PlaceboBaseline-Month 12: DenosumabBaseline-Month 24: Placebo/DenosumabBaseline-Month 24: Denosumab/DenosumabBaseline-Month 36: Placebo/DenosumabBaseline-Month 36: Denosumab/Denosumab
NasopharyngitisInfections and infestations1/80/161/80/161/83/16
HeadacheNervous system disorders1/82/161/82/161/83/16
AnaemiaBlood and lymphatic system disorders0/82/160/82/160/82/16
Iron deficiency anaemiaBlood and lymphatic system disorders0/80/161/80/161/80/16
CardiomyopathyCardiac disorders0/80/160/80/161/80/16
TachycardiaCardiac disorders0/81/160/82/160/82/16
Intracranial lipomaCongenital, familial and genetic disorders0/80/160/80/161/80/16
Delayed pubertyEndocrine disorders0/81/160/81/160/82/16
AstigmatismEye disorders1/80/161/80/161/80/16
Cataract subcapsularEye disorders1/80/161/80/161/80/16

Baseline characteristics

Full Analysis Set (FAS): all participants enrolled into the study.

Age, Continuous
Age, Continuous(Years)Denosumab/DenosumabPlacebo/DenosumabTotal
Mean13.8 ± 2.312.8 ± 2.113.4 ± 2.2
Sex: Female, Male
Sex: Female, Male(Participants)Denosumab/DenosumabPlacebo/DenosumabTotal
Female6410
Male10414
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Denosumab/DenosumabPlacebo/DenosumabTotal
Hispanic or Latino134
Not Hispanic or Latino15520
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Denosumab/DenosumabPlacebo/DenosumabTotal
American Indian or Alaska Native000
Asian303
Native Hawaiian or Other Pacific Islander000
Black or African American000
White13518
More than one race000
Unknown or Not Reported033
Bone Mineral Density (BMD) Z-score at Baseline
Bone Mineral Density (BMD) Z-score at Baseline(Z-score)Denosumab/DenosumabPlacebo/DenosumabTotal
Lumbar Spine-1.95 ± 1.03-3.60 ± 1.77-2.50 ± 1.51
Total Hip-3.14 ± 1.70-4.56 ± 2.08-3.58 ± 1.90
Femoral Neck-3.35 ± 1.91-4.78 ± 2.80-3.79 ± 2.25
08

Study locations

38 sites
  • Childrens Hospital of Los Angeles
    Los Angeles, California 90027, United States
  • AI Dupont Hospital for Children
    Wilmington, Delaware 19803, United States
  • Indiana University Hospital
    Indianapolis, Indiana 46202, United States
  • University of Minnesota Masonic Childrens Hospital Discovery Clinic
    Minneapolis, Minnesota 55454, United States
  • Metrohealth Medical Center
    Cleveland, Ohio 44109, United States
  • Nationwide Childrens Hospital
    Columbus, Ohio 43205, United States
  • Perth Childrens Hospital
    Nedlands, Western Australia 6909, Australia
  • Cliniques Universtaire Saint Luc Universite Catholique de Louvain
    Bruxelles, 1200, Belgium
  • Medical Centre Synexus Sofia EOOD
    Sofia, 1784, Bulgaria
  • Childrens Hospital of Eastern Ontario
    Ottawa, Ontario K1H 8L1, Canada
  • Centre Hospitalier Universitaire Sainte Justine
    Montreal, Quebec H3T 1C5, Canada
  • Center for Clinical and Basic Research Colombia
    Medellin, Antioquia 050021, Colombia
  • Solano y Terront Servicios Medicos Ltda - Unidad Integral de Endocrinologia Uniendo
    Bogota, Cundinamarca 110221, Colombia
  • Foscal Internacional-Fundacion Oftalmologica de Santander
    Floridablanca, Santander 681004, Colombia
  • Gandhi Medical College
    Hyderabad, Andhra Pradesh 500 025, India
  • Sir Ganga Ram Hospital
    New Delhi, Delhi 110 022, India
  • KLES Dr Prabhakar Kore Hospital and Medical Research Centre
    Belagavi, Karnataka 590010, India
  • Christian Medical College
    Vellore, Tamil Nadu 632 004, India
  • Azienda Ospedaliera Universitaria Meyer
    Firenze, 50139, Italy
  • Istituto Auxologico Italiano Istituto di Ricovero e Cura a Carattere Scientifico
    Milan, 20145, Italy
  • Azienda Ospedaliera Policlinico Umberto I
    Roma, 00161, Italy
  • RM Pharma Specialists SA de CV
    Ciudad de Mexico, 03100, Mexico
  • Instituto Nacional de Salud del Nino
    Brena, Lima Lima 5, Peru
  • Centro Especializado de Enfermedades Neoplasicas
    Arequipa, 040001, Peru
  • Hospital Nacional Alberto Sabogal Sologuren
    Callao, Callao 2, Peru
  • Clinica Angloamericana
    Lima, Lima 27, Peru
  • Centro de Investigacion Ricardo Palma
    Lima, Lima27, Peru
  • FSAI Scientific Center of Childrens Health of MoH of the RF
    Moscow, 119991, Russian Federation
  • SBEI of HPE First Moscow state medical university na I M Sechenov of MoH of Russian Federation
    Moscow, 119991, Russian Federation
  • SBHI of Novosibirsk region City Pediatric Clinical Hospital of Emergency Care
    Novosibirsk, 630007, Russian Federation
  • LLC Medical Technologies
    Saint Petersburg, 191025, Russian Federation
  • Ankara Universitesi Tip Fakultesi
    Ankara, 06590, Turkey
  • Ataturk Universitesi Tip Fakultesi
    Erzurum, 25240, Turkey
  • Marmara Universitesi Pendik Egitim Arastirma Hastanesi
    Istanbul, 34890, Turkey
  • Ege Universitesi Tip Fakultesi
    Izmir, 35100, Turkey
  • CI Dnipropetrovsk Regional Children Clinical Hospital of Dnipropetrovsk Regional Council
    Dnipro, 49100, Ukraine
  • Communal Institution of Healthcare Kharkiv City Clinical Children Hospital 16
    Kharkiv, 61075, Ukraine
  • National Childrens Specialized Hospital OHMATDYT
    Kyiv, 01025, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Dec 2021, 43 months.

Results were first posted in Jul 2024, 2 years 7 months after primary completion.

Of 35 industry-sponsored phase 3 interventional studies under Osteoporosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 46. This study's 43 months is above that.

Counting every sponsor, half of 45 studies reached it within 37 months; a quarter within 21 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2017
First posted
May 24, 2017
StartActual
May 7, 2018
Primary completionActual
Dec 13, 2021
CompletionActual
Dec 20, 2023
Results first posted
Jul 19, 2024
Last update
Jul 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03164928
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 24, 2017
Start date
May 7, 2018
Primary completion
Dec 13, 2021
Completion
Dec 20, 2023
Results posted
Jul 19, 2024
Last update
Jul 19, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion